The nation’s preeminent cancer hospitals are charging commercial health insurers anywhere from double to seven times their costs of acquiring cancer drugs, a new study shows.
Most top cancer institutions also are keeping their drug prices secret in direct violation of federal law, potentially exposing themselves to fines.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
